Clinical Trial

Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a randomized, double-blinded, placebo-controlled multicenter study to evaluate the safety and efficacy of DWN12088 in patients with Idiopathic Pulmonary Fibrosis.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2022-05-19; most recent amendment 2026-07-14.
Status change: Recruiting → Active, Not Recruiting 2026-07-14
Status change: Not Yet Recruiting → Recruiting 2023-02-13
Trial Details
NCT Number NCT05389215
Lead Sponsor Daewoong Pharmaceutical Co. LTD.
Conditions Idiopathic Pulmonary Fibrosis
Enrollment 102 participants
Start Date 2022-07-29
Primary Completion 2026-10-13 (estimated)
Study Completion 2027-01-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-16